Cochlear Ltd
Company Profile
Business description
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2026, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.
Contact
1 University Avenue
Macquarie University
SydneyNSW2109
AUST: +61 294286555
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
4,749
Cochlear Ltd News & Analysis
stocks
Reporting season was stronger than share prices suggest
markets
The grass is always greener: Rethinking Australian vs global equities
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,155.00 | 38.80 | -0.42% |
| CAC 40 | 8,306.15 | 27.38 | 0.33% |
| DAX 40 | 26,006.53 | 39.87 | -0.15% |
| Dow JONES (US) | 53,414.25 | 271.86 | -0.51% |
| FTSE 100 | 10,822.13 | 8.96 | -0.08% |
| HKSE | 25,272.21 | 140.91 | -0.55% |
| NASDAQ | 26,506.99 | 77.07 | -0.29% |
| Nikkei 225 | 66,610.62 | 210.77 | 0.32% |
| NZX 50 Index | 13,869.61 | 73.22 | -0.53% |
| S&P 500 | 7,718.60 | 29.11 | -0.38% |
| S&P/ASX 200 | 8,961.80 | 41.20 | -0.46% |
| SSE Composite Index | 3,941.87 | 9.17 | 0.23% |